Among others, with dalpiciclib, birociclib and lerociclib, there is a range of new CDK4/6i being evaluated in patients with hormone receptor-positive, HER2-negative aBC within phase III studies in China [44]. This evidence concerns the gene CDK4 and aneurysmal bone cyst.